Advertisement
Advertisement

GANX

GANX logo

Gain Therapeutics, Inc. Common Stock

1.77
USD
Sponsored
+0.15
+9.57%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

1.79

+0.02
+1.13%

GANX Earnings Reports

Positive Surprise Ratio

GANX beat 10 of 19 last estimates.

53%

Next Report

Date of Next Report
Mar 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.14
Implied change from Q3 25 (Revenue/ EPS)
--
/
-6.67%
Implied change from Q4 24 (Revenue/ EPS)
--
/
+27.27%

Gain Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, GANX reported earnings of -0.15 USD per share (EPS) for Q3 25, beating the estimate of -0.15 USD, resulting in a 1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +10.07% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an decrease of -6.67% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Gain Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 1.96%, and revenue of $0.00, 0% as expectations.
The stock price moved up 10.07%, changed from $2.68 before the earnings release to $2.95 the day after.
The next earning report is scheduled for Mar 25, 2026.
Based on 7 analysts, Gain Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement